Glioblastoma multiforme with long term survival

Neurology India

Volumn 53, Issue 3, 2005, Pages 329-332

  Deb, Prabal ^a   Sharma, Mehar Chand ^a   Mahapatra, Ashok Kumar ^a   Agarwal, Deepak ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Favourable outcome; Glioblastoma multiforme; Long term survival

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P27; PROTEIN P53;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HISTOLOGY; HUMAN; MALE; OLIGODENDROGLIA; OUTCOMES RESEARCH; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SURVIVAL RATE; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 27344459739     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.16934     Document Type: Article

References (14)

1. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, editors. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000;29-39.
2. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003;98:1745-8.
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
4. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, et al. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 2004;101:219-26.
5. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
6. Klein R, Molenkamp G, Sorensen N, Roggendorf W Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Childs Nerv Syst 1998;14:288-91
7. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999;46:183-8.
8. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002;8:180-7.
9. Sarkar C, Chattopadhyay P, Ralte AM, Mahapatra AK, Sinha S. Loss of heterozygosity of a locus in the chromosomal region of 17p13.3 is associated with increased cell proliferation in astrocytic tumors. Cancer Genet Cytogenet 2003;144:156-64.
10. Sarkar C, Ralte AM, Sharma MC, Mehta VS. Recurrent astrocytic tumors - a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 2002;16:335-42.
11. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11:1462-6.
12. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, et al. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res 1995;55:1941-5.
13. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003; 97:644-8.
14. Ozolek JA, Finkelstein SD, Couce ME. Gliosarcoma with epithelial differentiation: immunohistochemical and molecular characterization. A case report and review of the literature. Mod Pathol. 2004;17:739-45.